Use of polyclonal/monoclonal antibody therapies in transplantation (Q38769922)

6 September 2017

title

Use of polyclonal/monoclonal antibody therapies in transplantation (English)

1 reference

6 September 2017

1 reference

2

1 reference

6 September 2017

Melissa Y Yeung

1

1 reference

6 September 2017

Mohamed H Sayegh

series ordinal

3

1 reference

6 September 2017

language of work or name

English

0 references

publication date

16 January 2017

1 reference

Expert Opinion on Biological Therapy

6 September 2017

published in

1 reference

6 September 2017

volume

17

1 reference

6 September 2017

issue

3

1 reference

6 September 2017

page(s)

339-352

1 reference

Targeting CD28 to prevent transplant rejection

6 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Five-year follow up of thymoglobulin versus ATGAM induction in adult renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

A prospective, randomized, double-blinded comparison of thymoglobulin versus Atgam for induction immunosuppressive therapy: 10-year results

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

A comprehensive and quantitative analysis of the major specificities in rabbit antithymocyte globulin preparations

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Apoptosis and complement-mediated lysis of myeloma cells by polyclonal rabbit antithymocyte globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

A novel mechanism of action for anti-thymocyte globulin: induction of CD4 CD25 Foxp3 regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Rabbit ATG but not horse ATG promotes expansion of functional CD4 CD25highFOXP3 regulatory T cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Alemtuzumab: a novel monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibody-dependent cellular cytotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Rituximab and alemtuzumab induce a nonclassic, caspase-independent apoptotic pathway in B-lymphoid cell lines and in chronic lymphocytic leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Regulation of lymphocyte growth by antagonists of interleukin-2 or its cellular receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Induction Therapy for Kidney Transplant Recipients: Do We Still Need Anti-IL2 Receptor Monoclonal Antibodies?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Reduced exposure to calcineurin inhibitors in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Alefacept combined with tacrolimus, mycophenolate mofetil and steroids in de novo kidney transplantation: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

OSAKA trial: a randomized, controlled trial comparing tacrolimus QD and BD in kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Acute Rejection Rates and Graft Outcomes According to Induction Regimen among Recipients of Kidneys from Deceased Donors Treated with Tacrolimus and Mycophenolate

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Early outcomes of thymoglobulin and basiliximab induction in kidney transplantation: application of statistical approaches to reduce bias in observational comparisons

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Induction versus noninduction in renal transplant recipients with tacrolimus-based immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Limited dose monoclonal IL-2R antibody induction protocol after primary kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Rabbit antithymocyte globulin versus basiliximab in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Long-term safety and efficacy of antithymocyte globulin induction: use of integrated national registry data to achieve ten-year follow-up of 10-10 Study participants

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Prospective randomized controlled trial of rabbit antithymocyte globulin compared with IL-2 receptor antagonist induction therapy in kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation--efficacy and safety at five years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

The impact of IL2ra induction therapy in kidney transplantation using tacrolimus- and mycophenolate-based immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Interleukin-2 receptor antibody does not reduce rejection risk in low immunological risk or tacrolimus-treated intermediate immunological risk renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Induction Therapies in Live Donor Kidney Transplantation on Tacrolimus and Mycophenolate With or Without Steroid Maintenance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Alemtuzumab Induction in Renal Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Long-term cell monitoring of kidney recipients after an antilymphocyte globulin induction with and without steroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Prospective follow-up of primary CMV infections after 6 months of valganciclovir prophylaxis in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Sequential cytomegalovirus antigenemia monitoring in kidney transplant patients treated with antilymphocyte antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Infectious complications of antilymphocyte therapies in solid organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Choice of induction regimens on the risk of cytomegalovirus infection in donor-positive and recipient-negative kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Alemtuzumab induction and triple maintenance immunotherapy in kidney transplantation from donors after cardiac death

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Risk for post-transplant lymphoproliferative disorder after polyclonal antibody induction in kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Post-transplant lymphoproliferative disorders occurring after renal transplantation in adults: report of 230 cases from the French Registry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

OPTN/SRTR 2013 Annual Data Report: kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Identifying the patient at risk for post-transplant lymphoproliferative disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Is posttransplant lymphoproliferative disorder (PTLD) caused by any specific immunosuppressive drug or by the transplantation per se?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Posttransplantation lymphoproliferative disorder in kidney and heart transplant recipients receiving thymoglobulin: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Association of antibody induction immunosuppression with cancer after kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Subcutaneous administration of alemtuzumab in simultaneous pancreas-kidney transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Serum sickness after treatment with rabbit antithymocyte globulin in kidney transplant recipients with previous rabbit exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Safety and pharmacokinetics of daclizumab in pediatric renal transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Cost-minimization study comparing Simulect vs. Thymoglobulin in renal transplant induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Evolution of anti-CD20 monoclonal antibody therapeutics in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Targeting B cells in treatment of autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Mechanisms of killing by anti-CD20 monoclonal antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

B cell survival in intragraft tertiary lymphoid organs after rituximab therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

A single dose of rituximab does not deplete B cells in secondary lymphoid organs but alters phenotype and function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

B-cell-depleting induction therapy and acute cellular rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Rituximab as induction therapy after renal transplantation: a randomized, double-blind, placebo-controlled study of efficacy and safety.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Regulatory B cells are identified by expression of TIM-1 and can be induced through TIM-1 ligation to promote tolerance in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

TIM-1 signaling is required for maintenance and induction of regulatory B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Alemtuzumab (CAMPATH-1H) for the treatment of acute rejection in kidney transplant recipients: long-term follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

CXCL13: a novel biomarker of B-cell return following rituximab treatment and synovitis in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Tolerability and safety of rituximab (MabThera).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Banff 07 classification of renal allograft pathology: updates and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Reversal of acute cellular rejection after renal transplantation with Campath-1H.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

B cells mediate chronic allograft rejection independently of antibody production

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Microarray diagnosis of antibody-mediated rejection in kidney transplant biopsies: an international prospective study (INTERCOM).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Complement-binding anti-HLA antibodies and kidney-allograft survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Antibody-mediated rejection in kidney transplantation: a review of pathophysiology, diagnosis, and treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Comparison of combination Plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Impact of rituximab therapy for treatment of acute humoral rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Eculizumab treatment of acute antibody-mediated rejection in renal transplantation: case reports

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Eculizumab for salvage treatment of refractory antibody-mediated rejection in kidney transplant patients: case reports

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Eculizumab Therapy for Chronic Antibody-Mediated Injury in Kidney Transplant Recipients: A Pilot Randomized Controlled Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Belimumab: First targeted biological treatment for systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Tocilizumab for treating juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Therapeutic uses of anti-interleukin-6 receptor antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Blockade of interleukin-6 signaling augments regulatory T-cell reconstitution and attenuates the severity of graft-versus-host disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

A Phase I/II Trial of the Interleukin-6 Receptor-Specific Humanized Monoclonal (Tocilizumab) Intravenous Immunoglobulin in Difficult to Desensitize Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

First-in-human study of the safety and efficacy of TOL101 induction to prevent kidney transplant rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

A phase I/II randomized open-label multicenter trial of efalizumab, a humanized anti-CD11a, anti-LFA-1 in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

A phase 1, randomized ascending single-dose study of antagonist anti-human CD40 ASKP1240 in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Divergent immunoglobulin g subclass activity through selective Fc receptor binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Modulating Antibody Functionality in Infectious Disease and Vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Neonatal Fc receptor and IgG-based therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Inflammation Causes Resistance to Anti-CD20-Mediated B Cell Depletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Building better monoclonal antibody-based therapeutics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

One-year Results of the Effects of Rituximab on Acute Antibody-Mediated Rejection in Renal Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

Eculizumab and Splenectomy as Salvage Therapy for Severe Antibody-Mediated Rejection After HLA–Incompatible Kidney Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2017.1283400

10.1080/14712598.2017.1283400

21 January 2018

Identifiers

DOI

1 reference

6 September 2017

1 reference